Findings

What do systematic reviews say?

4,811 questions · 70,850 findings · 5,139 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 21.4%GRADE not reported 6,479 · 9.1%Very low 17,330 · 24.5%Low 17,814 · 25.1%Moderate 11,056 · 15.6%High 2,997 · 4.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings – strontium ranelate vs placebo

BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

BMD Z score (wrist) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Incidence of fractures · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Mobility · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Quality of life (back pain VAS score in cm) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

Adverse effects of treatment · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo or no treatment

Incidence of fractures · adults with β‐thalassaemia and osteoporosis

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Moderate

Bisphosphonates vs placebo or no treatment

Mobility · adults with β‐thalassaemia and osteoporosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo or no treatment

Quality of life (change in mean back pain) · adults with β‐thalassaemia and osteoporosis

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Very low

Bisphosphonates vs placebo or no treatment

Adverse effects of treatment · adults with β‐thalassaemia and osteoporosis

It is very uncertain whether summary of findings – bisphosphonates changes adverse effects of treatment compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
OR 15
2 studies · 143 participants
Very low

Intervention not reported

BMD Z score (total hip/femoral neck) · people with β‐thalassaemia and osteoporosis

It is very uncertain whether the intervention changes BMD Z score (total hip/femoral neck) (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Intervention not reported

BMD Z score (lumbar spine) · people with β‐thalassaemia and osteoporosis

It is very uncertain whether the intervention changes BMD Z score (lumbar spine) (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
MD 0.43 [0.1, 0.76]
1 study · 26 participants
Very low

Steroid implant vs sham

Proportion of participants with recurrence of uveitis · people with chronic non‐infectious uveitis

Steroid implant may leads to lower proportion of participants with recurrence of uveitis compared with sham procedure (low certainty).

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
RR 0.4 [0.3, 0.54]
2 studies · 282 participants
Low

Steroid implant vs standard‐of‐care therapy

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · people with chronic non‐infectious uveitis

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Steroid implant vs standard‐of‐care therapy

Proportion of eyes with cataract formation or progression, or surgery · people with chronic non‐infectious uveitis

Steroid implant may leads to higher proportion of eyes with cataract formation or progression, or surgery compared with standard‐of‐care therapy (low certainty).

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
RR 2.71 [2.06, 3.56]
Studies not reported
Low

Steroid implant vs standard‐of‐care therapy

Proportion of eyes with elevated IOP or receiving intervention · people with chronic non‐infectious uveitis

Steroid implant probably leads to higher proportion of eyes with elevated IOP or receiving intervention compared with standard‐of‐care therapy (moderate certainty).

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
RR 3.64 [2.71, 4.87]
Studies not reported
Moderate

Steroid implant vs standard‐of‐care therapy

Proportion of eyes with endophthalmitis**** · people with chronic non‐infectious uveitis

Steroid implant showed no clear difference in proportion of eyes with endophthalmitis**** compared with standard‐of‐care therapy (moderate certainty).

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
RR 7.3 [0.91, 58.72]
Studies not reported
Moderate

Steroid implant vs standard‐of‐care therapy

Proportion of eyes with retinal tear or detachment · people with chronic non‐infectious uveitis

Steroid implant showed no clear difference in proportion of eyes with retinal tear or detachment compared with standard‐of‐care therapy (moderate certainty).

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
RR 2.07 [0.51, 8.4]
Studies not reported
Moderate

Steroid implant vs sham

Mean difference in BCVA (logMAR) · people with chronic non‐infectious uveitis

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 153 participants
Low

Steroid implant vs sham

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · people with chronic non‐infectious uveitis

1 finding from 1 review

Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
Moderate